New study confirms safety of Temodex and shows it to be restrictive to the right organ

Double Bond Pharmaceutical has now completed a study investigating how much Temodex - the novel drug against brain cancer - spreads in the brain in rat. The purpose of the study was to follow and chart the concentration of the active substance and its metabolite in both brain and blood circulation. The study is one in the line of complementary preclinical studies to prove and strengthen proof of concept for the company's drug candidate against brain cancer - Temodex. The results show, among other things, that the concentration of active substance in rat brain is several times above the